Major Announcements - Sanhua Intelligent Control denied rumors of receiving large robot orders, confirming no undisclosed significant matters [1] - Hongdou Co. plans to acquire online business assets of Hongdou Home for 485 million yuan, enhancing its product matrix and sales synergy [1] - Yuehai Feed announced the cancellation of its wholly-owned subsidiary, which will not significantly impact overall business and profitability [1] Company Listings - Soft Control's subsidiary, Soft Control Technology, has received approval to be listed on the New Third Board starting October 16, 2025 [2] New Initiatives - Tianwei Video has been authorized to establish the "State-owned Assets and Enterprises Online Supervision and Security Operation (Shenzhen) Sub-center," enhancing its capabilities in online supervision [3] - Xinbo Co. plans to invest 1.5 million USD to establish a subsidiary in Singapore for international market expansion [4] Management Changes - Guangfa Securities announced the resignation of Deputy General Manager Li Qian due to personal work changes [5] Capital Increases - Aidi Pharmaceutical plans to increase capital by 10 million yuan in its affiliate Aipu Medical, maintaining ownership ratios [6] - Nar Holdings intends to acquire at least 51% of Feilai Testing, with an estimated investment of 350 to 400 million yuan [7] Financial Performance - Guanghua Technology reported a 1233.7% increase in net profit for the first three quarters, reaching 90.39 million yuan [8] - Zangzi Island expects a net loss of 29 to 35 million yuan for the first three quarters, impacted by market changes and asset impairments [9] - Shuo Beid expects a net profit increase of 2836.86% to 3203.96% for the third quarter, with an estimated profit of 16 to 18 million yuan [10] - Haiguang Information reported a 13.04% increase in net profit for the third quarter, driven by significant revenue growth [11] - Meinian Health anticipates a net profit increase of 70.51% to 151.7% for the first three quarters, despite a slight decline in revenue [12] - Tailin Micro expects a 118% increase in net profit for the first three quarters, with revenue growth of approximately 30% [14] - Yatai Co. forecasts a net profit increase of 97.38% to 113.3% for the first three quarters, attributed to market expansion and cost management [15] - He Sheng New Materials expects a net profit increase of 60% to 80% for the first three quarters, benefiting from improved gross margins [16] - Jiabiyou reported a 53.77% increase in net profit for the first three quarters, driven by increased sales of specific products [17] - Jiuzhou Pharmaceutical reported a 42.3% increase in net profit for the third quarter, attributed to sales growth and improved margins [18] - Gao Neng Environment reported a 1.05% decrease in net profit for the third quarter, despite a 15.18% increase for the first three quarters [19] - Zongyi Co. reported a 22.47% decrease in net profit for the third quarter, despite overall growth for the first three quarters [20] - Yiwei Communication expects a net profit decrease of 50% to 55% for the first three quarters, due to increased expenses [21] - Guoguang Chain reported a loss of 841.23 thousand yuan for the third quarter, despite a profit increase for the first three quarters [22] Strategic Partnerships - Dangsheng Technology signed a strategic cooperation framework agreement with Boyuan Co. to collaborate on sulfide solid electrolyte systems [23] - Dong'an Power secured five new market agreements in the third quarter, with an estimated total sales volume of 1 million units [24] - Mingxin Xuteng received a notification from a leading new energy vehicle client for interior materials development, with total sales expected to reach approximately 650 million yuan [24] Shareholding Changes - Shuhua Sports' actual controller plans to reduce holdings by up to 3% [25] - Nanling Technology's major shareholders plan to reduce holdings by up to 3.24% [26] - Xinhongze's controlling shareholder plans to reduce holdings by up to 3% [27] - Jintuo Co. plans to reduce holdings by up to 2.95% [28] - Neusoft Zai Bo's controlling shareholder plans to reduce holdings by up to 1.06% [29] Share Buybacks - Liou Co. plans to reduce repurchased shares by up to 135 million shares [30] - Kangchen Pharmaceutical plans to repurchase shares worth 50 to 100 million yuan [31] Fundraising Initiatives - Junpu Intelligent plans to raise up to 1.161 billion yuan through a private placement for various projects [32]

Core Viewpoint - The announcement from Aidi Pharmaceutical regarding the election of Tang Jieqing as the employee representative director of the third board of directors is a significant governance update for the company [2] Group 1 - Aidi Pharmaceutical will hold an employee representative conference on October 15, 2025 [2] - The employee representatives present at the conference voted in favor of electing Tang Jieqing as the employee representative director [2]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-061 江苏艾迪药业集团股份有限公司 关于 2025 年股票期权激励计划预留授予登记完成的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）及上海 证券交易所和中国证券登记结算有限责任公司上海分公司相关规定，江苏艾迪药 业集团股份有限公司（以下简称"公司"或"艾迪药业"）已完成了 2025 年股 票期权激励计划（以下简称"本次激励计划"）预留授予激励对象股票期权的登 记工作。现将相关事项公告如下： 一、本次激励计划已履行的决策程序和信息披露情况 1、2025 年 6 月 27 日，公司召开第三届董事会第四次会议，会议审议通过 了《关于公司<2025 年股票期权激励计划（草案）>及其摘要的议案》《关于公 司<2025 年股票期权激励计划实施考核管理办法>的议案》《关于提请股东会授 权董事会办理公司 2025 年股票期权激励计划相关事宜的议案》，相关议案已经 公司第三届董事会薪酬与考 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-058 江苏艾迪药业集团股份有限公司 关于选举职工代表董事的公告 公司于 2025 年 10 月 15 日召开职工代表大会，经与会职工代表表决，同意 选举唐洁璟女士（简历附后）为公司第三届董事会职工代表董事，任期自本次职 工代表大会审议通过之日起至公司第三届董事会任期届满之日止。 本次选举职工代表董事工作完成后，公司第三届董事会中兼任高级管理人员 职务以及由职工代表担任的董事人数未超过公司董事总数的二分之一，符合相关 法律法规的要求。 特此公告。 江苏艾迪药业集团股份有限公司董事会 2025 年 10 月 16 日 1 唐洁璟，女，加拿大英属哥伦比亚大学工商管理硕士，1988 年 4 月出生， 中国国籍，无境外居留权。唐洁璟于 2013 年任职于怡安翰威特上海分公司，从 事人力资源咨询顾问工作；2015-2017 年任职于朗诗集团，担任人力资源经理职 位，2021 年至今在江苏艾迪药业集团股份有限公司，先后任职人力资源总监、 投资高级经理岗位。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-059 江苏艾迪药业集团股份有限公司 关于向参股公司增资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏艾迪药业集团股份有限公司（以下简称"公司"、"艾迪药业"） 拟与北京安普生化科技有限公司（以下简称"北京安普"）共同以现金 方式合计向参股公司北京艾普医学检验实验室有限公司（以下简称"艾 普医学"）增资1,000.00万元，其中公司拟增资350.00万元认缴新增注册 资本350.00万元，北京安普拟增资650.00万元认缴新增注册资本650.00 万元。双方为按原持股比例进行的同比例增资，本次增资后，公司与北 京安普分别持有艾普医学的股权比例保持不变。 本次增资不构成《上市公司重大资产重组管理办法》规定的重大资产重 组。 本次关联交易实施不存在重大法律障碍。 本次关联交易已经公司第三届董事会独立董事2025年第二次专门会议、 第三届董事会第八次会议审议通过，关联董事傅和亮、史亚伦回避表决。 本事项在董事会审批权限范围内， ...

江苏世纪同仁律师事务所 关于江苏艾迪药业集团股份有限公司 2025年第三次临时股东会的 法 律 意 见 书 江苏艾迪药业集团股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》《上市公司股东会规则》和《上海证券交易所科创板上市公司自 律监管指引第1号 -- 规范运作》等法律、法规和规范性文件以及《公司章程》 的规定,本所受公司委托,指派本所律师出席公司 2025年第三次临时股东会, 并就本次股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序 以及表决结果的合法有效性等事项出具法律意见。 年第三次临时股东会会议资料》。 上述会议通知载明了本次股东会的召开时间、地点、会议召集人、会议审议 事项、出席对象、出席会议登记办法等事项,以及参与网络投票的股东的身份认 证与投票程序等内容。 为出具本法律意见书,本所律师对本次股东会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东会决议一并公告,并依法对本 法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求,按照律师行 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 证券代码：688488 证券简称：艾迪药业 公告编号：2025-060 （一） 股东会召开的时间：2025 年 10 月 15 日 （二） 股东会召开的地点：南京市玄武区玄武大道 699-18 号百家汇社区 20 栋 5 楼 江苏艾迪药业集团股份有限公司 2025年第三次临时股东会决议公告 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 91 | | --- | --- | | 普通股股东人数 | 91 | | 2、出席会议的股东所持有的表决权数量 | 200,408,977 | | 普通股股东所持有表决权数量 | 200,408,977 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 47.6276 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 47.6 ...

Core Viewpoint - Eddie Pharmaceuticals (688488.SH) announced a capital increase of 10 million yuan in its subsidiary, Aipu Medical, in collaboration with Beijing Anpu, maintaining their respective shareholding ratios [1] Group 1: Company Actions - The company plans to invest 3.5 million yuan to subscribe for an increase in registered capital of 3.5 million yuan [1] - Beijing Anpu will invest 6.5 million yuan to subscribe for an increase in registered capital of 6.5 million yuan [1] - The capital increase is proportionate to their original shareholding, ensuring that the ownership structure remains unchanged post-investment [1] Group 2: Industry Focus - Aipu Medical specializes in third-party medical testing services, with a focus on the HIV field and other potentially profitable areas of medical testing services [1]

Core Insights - The launch meeting for the Phase III clinical trial of ACC017, a new integrase inhibitor developed by Aidi Pharmaceutical Group, was held in Yangzhou, Jiangsu, with participation from key researchers and clinical units [1][3] - Aidi Pharmaceutical focuses on meeting clinical needs in the HIV field, emphasizing innovation and development of anti-HIV drugs [1][3] Group 1: Clinical Development - Dr. Fu Helian presented the research pipeline for Aidi's anti-HIV drugs, highlighting the clinical value and potential of ACC017 in terms of antiviral efficacy, safety, and resistance profile [3] - The project team introduced the Phase III clinical trial protocol and project plan, with experts discussing details and considerations for the trial's execution [4] Group 2: Market Position and Collaboration - Professor Zhang Fujie discussed international clinical research progress in HIV prevention and treatment, noting the high antiviral efficacy and clinical value of the domestic anti-HIV drug Ainomi [3] - Experts expressed confidence in the breakthrough of domestic integrase inhibitors and the importance of collaboration with clinical centers to advance the trial and contribute to innovative drug development in China [4]

Core Viewpoint - Eddie Pharmaceuticals announced the results of its key Phase III clinical study for the first "three-in-one" anti-HIV single-tablet combination innovative drug, Ainomit (Fubangde, ALT), which has been published in the prestigious medical journal BMC Medicine [1] Group 1 - The clinical study results were part of the SPRINT96 week extension trial for the treated conversion population [1] - BMC Medicine is a top-tier journal in the JCR and Chinese Academy of Sciences classification, with a five-year impact factor of 9.4 [1] - The published metrics of this study have already surpassed those of imported similar products [1]